| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
5-Ph-IAA targets the OsTIR1 (F74G) mutant protein in the auxin-inducible degron 2 (AID2) system. It is a ligand that binds to the engineered TIR1 protein, facilitating the ubiquitination and subsequent degradation of mAID-fused target proteins. This system allows for the rapid and efficient depletion of specific proteins to study their function in living cells.
|
|---|---|
| ln Vitro |
In HCT116 cells constitutively expressing OsTIR1 (F74G), 5-Ph-IAA (1 μM; 6 hours) promotes DHC1-mac degradation, suggesting that the AID2 system is more effective than the original AID system at producing conditionally altered cell lines [1].
5-Ph-IAA is a derivative of IAA that, together with an OsTIR1 (F74G) mutant, establishes the AID2 system. It induces rapid and efficient depletion of mAID-fused proteins with a DC50,6h of 17.0 nM and a T1/2 of 62.3 min. This allows for the study of protein function in living cells. |
| ln Vivo |
Tumor suppression results from 5-Ph-IAA (0-10 mg/kg; i.p.; daily; 7 days) administration to the AID2 system, which is sufficient to deplete mAID-BRD4 and TOP2A-mAC[1].
5-Ph-IAA causes tumor suppression in vivo when administered to the AID2 system. Doses of 0-10 mg/kg administered intraperitoneally daily for 7 days are sufficient to deplete mAID-BRDA and TOP2A-mAC, leading to tumor suppression. |
| Enzyme Assay |
The binding of 5-Ph-IAA to OsTIR1 (F74G) can be assessed using binding assays. The compound's ability to induce degradation of mAID-fused proteins is measured by Western blot analysis to determine the DC50 and degradation kinetics.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HCT116 cells Tested Concentrations: 1 µM Incubation Duration: 6 hrs (hours) Experimental Results: Depleted DHC1-mAC efficiently in HCT116 cells constitutively expressing OsTIR1(F74G). 5-Ph-IAA is used in cell-based assays to study protein function. Cells expressing OsTIR1 (F74G) and an mAID-fused target protein are treated with 5-Ph-IAA. The depletion of the target protein is monitored by Western blot or fluorescence microscopy. The effect on cellular processes, such as proliferation or signaling, is assessed. |
| Animal Protocol |
Animal/Disease Models: Balb/c-nu female mice (7 weeks old; 16–20 g ) bearing mAID-BRD4 and TOP2A-mAC xenograft tumours cells[1]
Doses: 0 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg Route of Administration: intraperitoneally (ip) injection; every day; 7 days Experimental Results: Displayed significant tumor suppression of mAID-BRD4 xenografts and TOP2A-mAC xenografts. 5-Ph-IAA is administered to animals (0-10 mg/kg; I.p.; daily; 7 days) to induce tumor suppression in the AID2 system. The depletion of target proteins and the effect on tumor growth are monitored. |
| ADME/Pharmacokinetics |
5-Ph-IAA has a molecular weight of 251.28 g/mol and a molecular formula of C16H13NO2. It is a solid that is soluble in DMSO. The compound is typically stored at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for 5-Ph-IAA are not extensively detailed, as it is a research compound. It is not intended for human or veterinary use. Standard laboratory safety precautions, including the use of personal protective equipment (PPE), should be followed when handling the compound.
|
| References | |
| Additional Infomation |
(5-Phenyl-1H-indol-3-yl)acetic acid is a raised auxin-induced degrader (AID) ligand that induces ubiquitination of the Arabidopsis IAA17-derived mini-AID (mAID) degrader fusion target protein in expression pore-modified rice TIR1 (OsTIR1) mutants (F74G or F74A) mediated by the Skp1-Cul1-F-box (SCF) E3 ligase complex.
5-Ph-IAA is a research-grade compound used as a ligand in the auxin-inducible degron 2 (AID2) system for the rapid and efficient depletion of specific proteins in living cells. This system is a valuable tool for studying protein function and validating drug targets. The compound is not approved for therapeutic use and is strictly for laboratory research. |
| Molecular Formula |
C16H13NO2
|
|---|---|
| Molecular Weight |
251.28
|
| Exact Mass |
251.095
|
| CAS # |
168649-23-8
|
| PubChem CID |
15207491
|
| Appearance |
White to light yellow solid powder
|
| LogP |
3.462
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
325
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C2=CC3=C(C=C2)NC=C3CC(=O)O
|
| InChi Key |
ACCCWYHBDGKDKN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H13NO2/c18-16(19)9-13-10-17-15-7-6-12(8-14(13)15)11-4-2-1-3-5-11/h1-8,10,17H,9H2,(H,18,19)
|
| Chemical Name |
2-(5-phenyl-1H-indol-3-yl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (397.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 1 mg/mL (3.98 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9796 mL | 19.8981 mL | 39.7962 mL | |
| 5 mM | 0.7959 mL | 3.9796 mL | 7.9592 mL | |
| 10 mM | 0.3980 mL | 1.9898 mL | 3.9796 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
